In agreement, we now report that in human astrocytomas, U87 cells treated with PP2, a selective Src inhibitor, showed a significant decrease in phosphorylation of FAK at Tyr861 (Figure 6(a)). Here, SRC is linked to astrocytoma (excluding glioblastoma).